Merck & Co Inc
NYSE: MRK
$99.14
-$0.03 (0.0%)
Closing Price on January 3, 2025
MRK Articles
Merck, Intel, JPMorgan Chase, and IBM led the Dow to a gain on Monday.
Published:
Last Updated:
Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for the treatment of metastatic non-small cell lung cancer met its primary endpoint.
Published:
Last Updated:
Incyte saw its shares make a sharp left turn on Friday after the firm gave an update on its late-stage collaboration with Merck. NewLink Genetics felt the sting as well.
Published:
Last Updated:
Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.
Published:
Last Updated:
Merck and Walmart were among Wednesday's biggest gainers on the Dow while Intel and Cisco were among the big losers.
Published:
Last Updated:
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
The Stifel view is that it is time for investors to take a more defensive posture, but that doesn’t mean selling everything and going to cash.
Published:
Last Updated:
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
Published:
Last Updated:
The Dow dropped in Tuesday trading, led by downturns at Disney, Merck, Nike, and DowDuPont.
Published:
Last Updated:
Walmart, General Electric, Merck, and Verizon were biggest losers on the DJIA Tuesday.
Published:
Last Updated:
The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety and income.
Published:
Last Updated:
Merck reported mixed fourth-quarter financial results before the markets opened on Friday.
Published:
Last Updated:
24/7 Wall St. has put together a preview of Exxon, Apple, Pfizer and other the Dow Jones Industrial Average companies scheduled to report their quarterly results this week.
Published:
Last Updated: